Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Bertilsson

Showing results (231-240 of 263) with videos related to

Pageof 27
Sort By:
British Journal of Clinical Pharmacology|June 20, 2003
Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with CaucasiansP Dalén, M-L Dahl, H-K Roh, et al.
Pharmacogenetics|December 11, 1999
High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islandsA Kaneko, J K Lum, L Yaviong, et al.
Clinical Pharmacology and Therapeutics|November 3, 1998
CYP2D6 polymorphism is not crucial for the disposition of selegilineH Scheinin, M Anttila, M L Dahl, et al.
Clinical Neuropharmacology|January 1, 1992
Interethnic differences in drug oxidation. Implications for the utilization of antidepressants and neurolepticsM L Dahl, I Johansson, Q Y Yue, et al.
Clinical Pharmacology and Therapeutics|December 2, 1998
Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitorsE Arlander, G Ekström, C Alm, et al.
Canadian Journal of Physiology and Pharmacology|March 1, 1995
Pharmacogenetics in clinical pharmacology and toxicologyT Inaba, D W Nebert, B Burchell, et al.
Clinical Pharmacology and Therapeutics|September 8, 2000
Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotypeK Herrlin, A Y Massele, G Rimoy, et al.
Lancet (London, England)|October 7, 1989
Disassociation between debrisoquine hydroxylation phenotype and genotype among ChineseQ Y Yue, L Bertilsson, M L Dahl-Puustinen, et al.
International Journal of Cancer|April 21, 1999
Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patientsI Persson, I Johansson, Y C Lou, et al.
Clinical Pharmacology and Therapeutics|July 25, 2008
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterolK P Kanebratt, U Diczfalusy, T Bäckström, et al.
Pageof 27

Showing results (231-240 of 263) with videos related to

Sort By:
Pageof 27
British Journal of Clinical Pharmacology|June 20, 2003
Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with CaucasiansP Dalén, M-L Dahl, H-K Roh, et al.
Pharmacogenetics|December 11, 1999
High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islandsA Kaneko, J K Lum, L Yaviong, et al.
Clinical Pharmacology and Therapeutics|November 3, 1998
CYP2D6 polymorphism is not crucial for the disposition of selegilineH Scheinin, M Anttila, M L Dahl, et al.
Clinical Neuropharmacology|January 1, 1992
Interethnic differences in drug oxidation. Implications for the utilization of antidepressants and neurolepticsM L Dahl, I Johansson, Q Y Yue, et al.
Clinical Pharmacology and Therapeutics|December 2, 1998
Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitorsE Arlander, G Ekström, C Alm, et al.
Canadian Journal of Physiology and Pharmacology|March 1, 1995
Pharmacogenetics in clinical pharmacology and toxicologyT Inaba, D W Nebert, B Burchell, et al.
Clinical Pharmacology and Therapeutics|September 8, 2000
Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotypeK Herrlin, A Y Massele, G Rimoy, et al.
Lancet (London, England)|October 7, 1989
Disassociation between debrisoquine hydroxylation phenotype and genotype among ChineseQ Y Yue, L Bertilsson, M L Dahl-Puustinen, et al.
International Journal of Cancer|April 21, 1999
Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patientsI Persson, I Johansson, Y C Lou, et al.
Clinical Pharmacology and Therapeutics|July 25, 2008
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterolK P Kanebratt, U Diczfalusy, T Bäckström, et al.
Pageof 27